TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28624898

Group type: EXPERIMENTAL
Intervention: Integrated diabetes care programme (DIAPREM) with quarterly clinical appointments
Number of subjects: 150

Group type: COMPARATOR
Intervention: Traditional care (Control Group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Integrated diabetes care programme (DIAPREM)
Number of subjects: 150
Study: 25197740

Group type: EXPERIMENTAL
Intervention: Mechanical cleaning with interdental brushes combined with cetylpyridinium chloride (0.3% CPC) gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mechanical cleaning with interdental brushes alone
Number of subjects: 40
Study: 23537123

Group type: EXPERIMENTAL
Intervention: OFD + IMP
Number of subjects: 42

Group type: COMPARATOR
Intervention: OFD alone
Number of subjects: 42
Study: 22511260

Group type: EXPERIMENTAL
Intervention: AGE-LDL-ICs
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: oxLDL-ICs
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: AGE-LDL-ICs and oxLDL-ICs
Number of subjects: 517
Study: 19299272

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) with anti-inflammatory agent (60 mg oral acemetacine twice daily for 10 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (Ca-nadroparin 190 IUAxa/kg in a single dose)
Number of subjects: 50
Study: 17516022

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg once-yearly for 2, 3 or 5 years
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg once-yearly
Number of subjects: 119

Group type: COMPARATOR
Intervention: Calcium only
Number of subjects: 119
Study: 15468607

Group type: EXPERIMENTAL
Intervention: Trazodone (50-100 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Zaleplon (10-20 mg)
Number of subjects: 15
Study: 11790899

Group type: EXPERIMENTAL
Intervention: Partial body weight (PBW) treadmill training
Number of subjects: 10
Study: 12886697

Group type: EXPERIMENTAL
Intervention: Salt loaded (300 mmol Na+/day) for 4 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Salt restricted (25 mmol Na+/day) for 4 days
Number of subjects: 27
Study: 8160096

Group type: EXPERIMENTAL
Intervention: 30 Gy/ten fractions/two weeks (Group A)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 50 Gy/20 fractions/four weeks (Group B)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 30 Gy/ten fractions/two weeks (Group C)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 20 Gy/five fractions/one week (Group D)
Number of subjects: 162
Study: 3049185

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30411180

Group type: EXPERIMENTAL
Intervention: ASPREE participants (intervention group)
Number of subjects: 18714
Study: 28167747

Group type: EXPERIMENTAL
Intervention: Integrated Collaborative Care Team (ICCT) services
Number of subjects: 500

Group type: COMPARATOR
Intervention: Hospital-based treatment as usual
Number of subjects: 500
Study: 29911601

Group type: EXPERIMENTAL
Intervention: Oral oxycodone (OXY)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous morphine (IVM) followed by codeine
Number of subjects: 80
Study: 23734943

Group type: EXPERIMENTAL
Intervention: On-site integrated psychiatric care
Number of subjects: 316

Group type: COMPARATOR
Intervention: Off-site non-integrated psychiatric care
Number of subjects: 316
Study: 21140258

Group type: EXPERIMENTAL
Intervention: Sublingual Salvinorin A (SA) up to 4 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 18245546

Group type: EXPERIMENTAL
Intervention: OGX-011 at 640 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Docetaxel (30 mg/m2 weekly for 5 of 6 weeks or 75 mg/m2 every 3 weeks)
Number of subjects: 40
Study: 16989201

Group type: EXPERIMENTAL
Intervention: Dry air radon baths (DARB) with radon concentration 40 nCi/l
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dry air radon baths (DARB) with radon concentration 20 nCi/l
Number of subjects: 0
Study: 12975739

Group type: EXPERIMENTAL
Intervention: Rapacuronium 1.5 mg/kg with neostigmine
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Rapacuronium 1.5 mg/kg without neostigmine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Mivacurium 0.25 mg/kg
Number of subjects: 61
Study: 10783183

Group type: EXPERIMENTAL
Intervention: Intensive clinical case management
Number of subjects: 268

Group type: COMPARATOR
Intervention: Hospital-based expanded brokerage case management
Number of subjects: 268
Study: 8689374

Group type: EXPERIMENTAL
Intervention: Clinicians' housing recommendations
Number of subjects: 86

Group type: COMPARATOR
Intervention: Consumers' housing preferences
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Specific housing features
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Clinicians' consideration of social background and health status
Number of subjects: 86
Study: 1679961

Group type: EXPERIMENTAL
Intervention: Iosimide (low osmolar nonionic contrast media)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Iopromide (nonionic contrast media)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Iopamidol (nonionic contrast media)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Sodium-meglumine-diatrizoate (high osmolar ionic contrast media)
Number of subjects: 198
Study: 6594473

Group type: EXPERIMENTAL
Intervention: 2 million units aqueous penicillin G intravenously every four hours for a total of 12 doses (two days) postoperatively
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo intravenously every four hours for a total of 12 doses (two days) postoperatively
Number of subjects: 40
Study: 3083741

Group type: EXPERIMENTAL
Intervention: Almitrine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29471812

Group type: EXPERIMENTAL
Intervention: 12-week mild-calorie-restriction (300 kcal/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 27879604

Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy for 5 days after primary closure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional dressing
Number of subjects: 100
Study: 24388729

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Methohexital
Number of subjects: 38
Study: 23147642

Group type: EXPERIMENTAL
Intervention: Calf skeletal muscle index (SMI=D2/Ri)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Bioimpedance muscle indices
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Calf intracellular resistance
Number of subjects: 106
Study: 20942667

Group type: EXPERIMENTAL
Intervention: Zidovudine and lamivudine plus nevirapine
Number of subjects: 164

Group type: COMPARATOR
Intervention: Zidovudine and lamivudine plus ritonavir-boosted lopinavir
Number of subjects: 164
Study: 19032906

Group type: EXPERIMENTAL
Intervention: Krypton yellow laser photocoagulation around the hole margin with oral placebo (vitamin B1)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Oral placebo (vitamin B1) only
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Krypton yellow laser photocoagulation
Number of subjects: 27
Study: 15667973

Group type: EXPERIMENTAL
Intervention: RT plus hypnotherapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard curative RT alone
Number of subjects: 69
Study: 12523894

Group type: EXPERIMENTAL
Intervention: Chronic suppressive oral acyclovir
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Chronic suppressive oral acyclovir targeting patients with a history of stromal keratitis
Number of subjects: 703
Study: 10656227

Group type: EXPERIMENTAL
Intervention: Vitamin E 500 U/day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control
Number of subjects: 46
Study: 8660020

Group type: EXPERIMENTAL
Intervention: Music intervention (listening to choice of music before surgery)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Preoperative instruction alone (control group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 42
Study: 1988724

Group type: EXPERIMENTAL
Intervention: Potassium-magnesium citrate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Potassium citrate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Magnesium citrate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Potassium chloride
Number of subjects: 14
Study: 6340249

Group type: EXPERIMENTAL
Intervention: O‐(beta‐Hydroxyethyl)‐rutoside administered intravenously daily before each radiation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study: 30809646

Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle intervention (7 group sessions)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 96
Study: 29740973

Group type: EXPERIMENTAL
Intervention: Modified Unconditional Cash Transfer (6 transfers from April) plus 4 months supplementary feeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Unconditional Cash Transfer (4 transfers between June and September) plus 4 months supplementary feeding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified Unconditional Cash Transfer plus supplementary feeding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both arms (Modified UCT and Standard UCT)
Number of subjects: 0
Study: 27537756

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (ventilation group)
Number of subjects: 332

Group type: COMPARATOR
Intervention: No mechanical ventilation (deflation group)
Number of subjects: 332
Study: 25222104

Group type: EXPERIMENTAL
Intervention: Audiovisual (AV) mode
Number of subjects: 23

Group type: COMPARATOR
Intervention: Auditory-only (AO) mode
Number of subjects: 23

Group type: COMPARATOR
Intervention: 10 dB SL (re:SRT)
Number of subjects: 23
Study: 22981031

Group type: EXPERIMENTAL
Intervention: Pravastatin, vitamin E, and homocysteine lowering therapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 20522572

Group type: EXPERIMENTAL
Intervention: CPX-1 (cardiopulmonary exercise test 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CPX-0 (cardiopulmonary exercise test 0)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peak Vo2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ventilatory efficiency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ventilatory-derived anaerobic threshold
Number of subjects: 0
Study: 17989119

Group type: EXPERIMENTAL
Intervention: Patients with one or fewer major breaks per session
Number of subjects: 98

Group type: COMPARATOR
Intervention: Patients with more than one major break per session
Number of subjects: 98
Study: 16045048

Group type: EXPERIMENTAL
Intervention: Contact with researchers
Number of subjects: 0
Study: 11377644

Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg twice daily)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 9647605

Group type: EXPERIMENTAL
Intervention: Cysteinyl leukotriene receptor antagonist (zafirlukast)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-lipoxygenase inhibitor (zileuton)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antileukotriene agents (general)
Number of subjects: 0
Study: 8049043

Group type: EXPERIMENTAL
Intervention: Closure with a running 6‐0 fast‐absorbing catgut suture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Subcuticular closure with a 5‐0 polypropylene suture (Prolene)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 20
Study: 2542682

Group type: EXPERIMENTAL
Intervention: naloxone (0.8 mg i.v.)
Number of subjects: 17

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study: 1146722

Group type: EXPERIMENTAL
Intervention: Tocopherol-stripped safflower oil containing 88 g of polyunsaturated fatty acids and 2.3 mg of tocopherols.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no supplementation, low vitamin E diet).
Number of subjects: 35
Study: 30418340

Group type: EXPERIMENTAL
Intervention: Modified Sinaki exercises
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Nordic Walking workout
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Combination of modified Sinaki exercises and Nordic Walking
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (drugs only)
Number of subjects: 91
Study: 28609475

Group type: EXPERIMENTAL
Intervention: Selenium and coenzyme Q10 supplementation
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 26404895

Group type: EXPERIMENTAL
Intervention: Daily exercise programme
Number of subjects: 469
Study: 25514490

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 70

Group type: COMPARATOR
Intervention: 2% lidocaine with 0.2% epinephrine
Number of subjects: 70
Study: 22310310

Group type: EXPERIMENTAL
Intervention: Nitric oxide synthase (NOS) inhibition via intra-arterial infusion of N(G)-monomethyl-L-arginine (L-NMMA)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Passive limb movement (control)
Number of subjects: 6
Study: 20027346

Group type: EXPERIMENTAL
Intervention: IFN inductor anaferon (pediatric formulation)
Number of subjects: 0
Study: 17463304

Group type: EXPERIMENTAL
Intervention: 100 mg indomethacin per day
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15120769

Group type: EXPERIMENTAL
Intervention: Strong opioids
Number of subjects: 100

Group type: COMPARATOR
Intervention: WHO guidelines
Number of subjects: 100
Study: 11458138

Group type: EXPERIMENTAL
Intervention: Multicomponent targeted intervention (MTI) to prevent delirium
Number of subjects: 852

Group type: COMPARATOR
Intervention: Usual hospital care
Number of subjects: 852
Study: 9017526

Group type: EXPERIMENTAL
Intervention: Sustained-release methylphenidate (MSR) 20-40 mg/day
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sustained-release methylphenidate (MSR)
Number of subjects: 8
Study: 8506913

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 2000 mg
Number of subjects: 10
Study: 2951051

Group type: EXPERIMENTAL
Intervention: 2 mg doxazosin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 4 mg doxazosin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 8 mg doxazosin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Doxazosin (2, 4, and 8 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 18
Study: 29463933

Group type: EXPERIMENTAL
Intervention: Toe resistance training combined with traditional aerobic exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Aerobic exercise only (Control)
Number of subjects: 12
Study: 26414236

Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy (MC)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 104
Study: 23994382

Group type: EXPERIMENTAL
Intervention: Pegasys (PegIFNα) weekly dosing of 360 μg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Viread (tenofovir disoproxil fumarate, TDF) daily dose of 300 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of Pegasys and Viread
Number of subjects: 28

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 28
Study: 22743137

Group type: EXPERIMENTAL
Intervention: Early hCG administration (hCG 5000 IU, IM when leading follicle diameter 16.0-16.9 mm)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Late hCG administration (hCG 5000 IU, IM when leading follicle diameter 18.0-18.9 mm)
Number of subjects: 612
Study: 20845002

Group type: EXPERIMENTAL
Intervention: Flavocoxid (500 mg twice daily)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Naproxen (500 mg twice daily)
Number of subjects: 220
Study: 18450119

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 16630151

Group type: EXPERIMENTAL
Intervention: PLA(2) peptide vaccine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (untreated subjects)
Number of subjects: 12
Study: 14714934

Group type: EXPERIMENTAL
Intervention: Computer-animated tutor (Baldi) for vocabulary and grammar learning
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Computer-animated tutor (Baldi)
Number of subjects: 14
Study: 10618542

Group type: EXPERIMENTAL
Intervention: HIV SF2 gp120/MF59 vaccine (50 microg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 8839901

Group type: EXPERIMENTAL
Intervention: Fadrozole 1 mg twice daily
Number of subjects: 212

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg daily
Number of subjects: 212
Study: 8136396

Group type: EXPERIMENTAL
Intervention: Alfentanil (10 to 20 micrograms/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fentanyl (1 to 2 micrograms/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alfentanil and Fentanyl
Number of subjects: 40
Study: 3323603

Group type: EXPERIMENTAL
Intervention: Exercise (40% of VO2 max)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propranolol and metoprolol (beta adrenergic antagonists)
Number of subjects: 20
Study: 31929405

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Control group (matched controls with no severe outcomes)
Number of subjects: 447
Study: 29866385

Group type: EXPERIMENTAL
Intervention: Brief behavioral treatment (BT) based on motivational interviewing and cognitive behavioral therapy
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Medication-assisted treatment (MAT) with extended-release injectable naltrexone (XR-NTX) for alcohol use disorder or buprenorphine/naloxone (BUP/NX) for opioid use disorder
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Collaborative care (CC) intervention
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Receiving at least one session of BT
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Self-stigma
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Diagnosis of heroin abuse or dependence
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Being homeless
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Being of 'other' or 'multiple' races compared to being White
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Having been arrested within 90 days of baseline
Number of subjects: 392
Study: 26673981

Group type: EXPERIMENTAL
Intervention: Infliximab (n = 11)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Second dose of IVIG (n = 32)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Coronary artery outcomes and adverse events
Number of subjects: 43
Study: 25671931

Group type: EXPERIMENTAL
Intervention: Deferiprone (75 mg/kg in three divided doses orally)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Deferrioxamine (50 mg/kg/24hrs for 5 days/week as parental infusion)
Number of subjects: 134
Study: 21755329

Group type: EXPERIMENTAL
Intervention: MRI after six adjuvant TMZ courses
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: (201)Tl SPECT after three adjuvant TMZ courses
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Baseline MRI in recurrent glioma patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Follow-up MRIs during TMZ in recurrent glioma patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Baseline (201)Tl SPECT in recurrent glioma patients
Number of subjects: 46
Study: 19384263

Group type: EXPERIMENTAL
Intervention: MeNZB vaccine (25 mug) administered with routine immunizations and a fourth dose at 10 months (n = 250)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Routine immunizations only (Group 2, n = 125)
Number of subjects: 375
Study: 17569575

Group type: EXPERIMENTAL
Intervention: Computer reminders for antibiotic prescriptions
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Computer reminders for asthma/COPD prescriptions
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Specific recommendations (quinolones for cystitis, corticosteroids for COPD, antibiotics for acute sore throat)
Number of subjects: 53
Study: 15222528

Group type: EXPERIMENTAL
Intervention: loratadine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: fexofenadine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: cetirizine
Number of subjects: 31

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study: 12081584

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 200

Group type: COMPARATOR
Intervention: Calcium-based phosphate binders
Number of subjects: 200
Study: 9764988

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (10 mg kg(‐1).d(‐1), given in single daily doses)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (10 mg kg(‐1).d(‐1), given in multiple daily doses)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 48
Study: 7932289

Group type: EXPERIMENTAL
Intervention: Non-psychotic unipolar depression and alcoholism (39 families)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Non-psychotic unipolar depression without alcoholism (160 families)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Alcoholism without psychotic or major affective disorders (64 families)
Number of subjects: 372

Group type: COMPARATOR
Intervention: General population (109 families)
Number of subjects: 372
Study: 3265347

Group type: EXPERIMENTAL
Intervention: Low-dose perioperative interferon-alpha (r-HuIFN alpha), 2 megaunits daily for 1 week starting the evening before surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study: 31994003

Group type: EXPERIMENTAL
Intervention: Group embryo culture under low‐oxygen tension in benchtop incubators
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control culture strategy (individual culture under atmospheric oxygen tension in large‐box incubators)
Number of subjects: 148
Study: 29473352

Group type: EXPERIMENTAL
Intervention: Pricking and cupping combined with rehabilitation training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medication (Baclofen 10 mg, 3 times a day for 4 weeks)
Number of subjects: 60